Market Overview

Wedbush Downgrades CytomX Due To Lack Of Clarity On Development Paths

Wedbush Downgrades CytomX Due To Lack Of Clarity On Development Paths

CytomX Therapeutics Inc (NASDAQ: CTMX) reported disappointing third-quarter results and lacks clarity into the path forward for its wholly-owned PD-L1 Probody CX-072, according to Wedbush.

The Analyst

Wedbush’s Robert Driscoll downgraded CytomX Therapeutics from Outperform to Neutral while reducing the price target from $25 to $8.

The Thesis

CytomX Therapeutics reported a net loss of $23.7 million, or 52 cents per share, versus Wedbush’s estimate of a net loss of 33 cents per share, due to lower-than-expected revenue recognition, Driscoll said in the downgrade note.

The company had $325.7 million in cash and equivalents at the end of the third quarter. The analyst mentioned that although this can fund ongoing operations at least through the fourth quarter of 2021, CytomX Therapeutics could initiate an equity financing in the first quarter of that year.

Noting a lack of short-term catalysts, Driscoll said that there was lack of an ultimate development path for the company’s CX-072 compound. He wrote, “Although we note PD-1 refractory melanoma patients have few approved options available to them, the contribution of a PD-(L)1 to a combination regimen in this line of treatment remains unclear.”

The analyst said that CytomX Therapeutics had plans to initiate several additional combination studies of CX-072 which may provide clarity into the ultimate registration pathways.

Price Action

Shares of CytomX Therapeutics were trading down 6.72% at $5.55 at time of publication Monday.

Latest Ratings for CTMX

Nov 2019Initiates Coverage OnBuy
Nov 2019DowngradesOutperformNeutral
Jun 2019Initiates Coverage OnBuy

View More Analyst Ratings for CTMX
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Earnings News Downgrades Price Target Analyst Ratings General


Related Articles (CTMX)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Mid-Day Market Update: Carbonite Jumps Following Acquisition News; Lipocine Shares Plummet

Benzinga Unveils Fintech Innovators To Be Honored At 5th Annual Fintech Awards